• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CORCYM CANADA CORP. PERCEVAL SUTURELESS AORTIC HEART VALVE; TISSUE HEART VALVE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CORCYM CANADA CORP. PERCEVAL SUTURELESS AORTIC HEART VALVE; TISSUE HEART VALVE Back to Search Results
Model Number PVS
Device Problem Patient-Device Incompatibility (2682)
Patient Problem Heart Block (4444)
Event Type  Injury  
Event Description
Received the information from a published paper "use of sutureless valve in aortic root enlargement" by silvana f.Marasco.Based on the information provided in this paper, perceval valve was implanted in the patients with small annulus after performing a root enlargement.As reported, result of the study post-operative course was unremarkable in all patients except for the patient who had a double valve replacement and required a permanent pacemaker insertion on day 5 post-operatively for a complete heart block.Follow-up (median 2 years, range 1 month to 4 years), has shown no paravalvular leak in any of the patients and transvalvular pressure gradients remained low (12 mmhg¿21 mmhg) at the latest follow-up.No further information is available at this time.
 
Manufacturer Narrative
H3 other text : device remained implanted.
 
Manufacturer Narrative
Updated fields: b4, g3, g6, h2, h6.Manufacturer attempted to follow up with author, but no further information has yet been received despite manufacturer multiple attempts of follow up.Since limited information is available, the definitive root cause of the reported event could not be established at this time.Conduction disorders are common in patients with aortic valve diseases.As a result, it is common for patients to receive permanent pacemaker implantation after aortic valve replacement.Risk factors include preexisting conducting disease and preoperative aortic regurgitation.This event is, therefore, a known, inherent risk of the procedure, and it is listed among the potential adverse events in the perceval ifu.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PERCEVAL SUTURELESS AORTIC HEART VALVE
Type of Device
TISSUE HEART VALVE
Manufacturer (Section D)
CORCYM CANADA CORP.
5005 north fraser way
burnaby, bc V5J 5 M1
CA  V5J 5M1
Manufacturer (Section G)
CORCYM CANADA CORP.
5005 north fraser way
burnaby, bc V5J 5 M1
CA   V5J 5M1
Manufacturer Contact
laura mannino
5005 north fraser way
burnaby, bc V5J 5-M1
CA   V5J 5M1
MDR Report Key18744236
MDR Text Key335813381
Report Number3004478276-2024-00114
Device Sequence Number1
Product Code LWR
Combination Product (y/n)N
Reporter Country CodeAS
PMA/PMN Number
P150011
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial
Report Date 02/20/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/20/2024
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Model NumberPVS
Device Catalogue NumberTBD
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Date Manufacturer Received01/23/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-